NCT04453085View on ClinicalTrials.gov

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

May 2, 2025

Study Completion Date

May 2, 2025

Conditions
Mucopolysaccharidosis I
Interventions
DRUG

JR-171

Intravenous (IV) infusion

Trial Locations (6)

94609

UCSF Benioff Children's Hospital Oakland, Oakland

Unknown

Hospital de Clínicas de Porto Alegre, Porto Alegre

Instituto de Genética e Erros Inatos do Metabolismo - IGEIM, São Paulo

Fukuoka Children's Hospital, Fukuoka

National Hospital Organization Kokura Medical Center, Kitakyushu

Osaka Metropolitan University Hospital, Osaka

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04453085 - An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I) | Biotech Hunter | Biotech Hunter